Polycythemia vera is a blood disorder in which the body creates too many red blood cells. These extra red cells make blood thicker than normal. The thickened blood flows slower and may clot within body. Red blood cells carry oxygen to organs and tissues throughout the body. If the blood moves too slowly or clots, the cells cannot deliver enough oxygen. This situation can cause serious complications including heart attack, stroke, and heart failure. There are two types of polycythemia vera, which include primary polycythemia vera and secondary polycythemia vera. Polycythemia vera gets worse with time if remain undiagnosed and can be life-threatening. Polycythemia vera can be treatable but is not curable. Polycythemia vera treatment may include phlebotomy and drug therapy. Phlebotomy involves the removal of blood from the body. Drug therapy involves the use of Hydroxyurea and Interferon-alfa. Patients who do not respond to hydroxyurea are treated with ruxolitinib (jakafi) or busulfan. At times a low dose of aspirin, allopurinol and antihistamines are also preferred for polycythemia vera treatment. Givinostat is an emerging drug in global polycythemia vera treatment market.
Market Dynamics
The increasing incidence of polycythemia vera, rising research and development activities for the development of novel therapeutics for the treatment of polycythemia vera, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, are the major factors that are expected to drive growth of the global polycythemia vera therapeutics market over the forecast period.
For instance, according to the National Organization for Rare Disorders, polycythemia vera affects slightly more men than women and the disorder is estimated to affect around 44 to 57 per 100,000 people in the U.S. each year It occurs most often in individuals over 60 years old, but can affect individuals of any age. It is extremely rare in individuals under the age of 20.
Key features of the study
• This report provides in-depth analysis of the global polycythemia vera therapeutics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global polycythemia vera therapeutics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Pfizer Inc, Galena Biopharma, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, PharmaEssentia Corporation, Bayer AG, Mylan N.V., Teva Pharmaceuticals Industries Ltd, GlaxosmithKline plc, ANP Technologies, INC., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc, Karus Therapeutics Limited, and Miragen Therapeutics, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global polycythemia vera therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global polycythemia vera therapeutics market
Market Segmentation
• By Disease Type (Revenue, USD Bn, 2021-2033)
o Primary Polycythemia Vera
o Secondary Polycythemia Vera
• By Drug Class (Revenue, USD Bn, 2021-2033)
o Antimetabolite
o Kinase Inhibitors
o Alpha Interferon
o Selective Serotonin Reuptake Inhibitors
o Others
• By Route of Administration (Revenue, USD Bn, 2021-2033)
o Oral
o Intravenous
o Intramuscular
o Subcutaneous
• By Distribution Channel (Revenue, USD Bn, 2021-2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• By Region (Revenue, USD Bn, 2021-2033)
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Key Players
o Pfizer Inc.
o Galena Biopharma
o Bristol-Myers Squibb Company
o Novartis AG
o Eli Lilly and Company
o PharmaEssentia Corporation
o Bayer AG
o Mylan N.V.
o Teva Pharmaceuticals Industries Ltd
o GlaxosmithKline plc
o ANP Technologies, INC.
o Hoffmann-La Roche Ltd.
o Gilead Sciences, Inc.
o Karus Therapeutics Limited
o Miragen Therapeutics, Inc.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Disease Type
Market Snapshot, By Drug Class
Market Snapshot, By Route of Administration
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Product Approval
o Collaboration/Merge/Acquisition
o Regulatory Landscape
o PEST Analysis
o Porter’s Five Forces Analysis
o Epidemiology
o Robust Pipeline Analysis
4. Polycythemia Vera Therapeutics Market, By Disease Type, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Primary Polycythemia Vera
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Secondary Polycythemia Vera
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
5. Polycythemia Vera Therapeutics Market, By Drug Class, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Antimetabolite
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Kinase Inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Alpha Interferon
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Selective Serotonin Reuptake Inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
6. Polycythemia Vera Therapeutics Market, By Route of Administration, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Intravenous
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Intramuscular
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Subcutaneous
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
7. Polycythemia Vera Therapeutics Market, By Distribution Channel, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
8. Polycythemia Vera Therapeutics Market, By Region, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 – 2033, (USD Billion)
o North Africa
o Central Africa
o South Africa
9. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profile
Pfizer Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Galena Biopharma
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Bristol-Myers Squibb Company
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Novartis AG
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Eli Lilly and Company
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
PharmaEssentia Corporation
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Bayer AG
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Mylan N.V.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Teva Pharmaceuticals Industries Ltd
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
GlaxosmithKline plc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
ANP Technologies, INC.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
F. Hoffmann-La Roche Ltd.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Gilead Sciences, Inc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Karus Therapeutics Limited
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Miragen Therapeutics, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Analyst Views
10. Section
o References
o Research Methodology
o About Us
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們